SpinaFX is at the forefront of developing innovative medical solutions aimed at treating back pain associated with contained lumbar herniated discs. Their flagship technology, the Triojection™ System, utilizes a patented approach that combines a computer-controlled console with an ozone generation chamber, allowing for the precise delivery of a mixture of oxygen and ozone gas directly into the affected disc. This minimally invasive, image-guided therapy is designed to provide rapid and sustained relief for patients who have not found success with conservative treatments or wish to avoid surgery. The system adheres to strict aseptic principles, ensuring sterile delivery of ozone, which is crucial for patient safety and treatment efficacy.

The therapeutic mechanism of the Triojection™ System involves the injection of ozone into the nucleus pulposus of the disc, which has been shown to dehydrate and break down proteins, leading to a reduction in disc bulging and associated pain. Research indicates that this method can significantly reduce the volume of herniated discs, thereby alleviating nerve root compression. Additionally, ozone's antimicrobial properties help reduce the risk of infection, further enhancing the treatment's effectiveness. SpinaFX aims to fill a critical gap in the treatment landscape for radiculopathy, providing a viable alternative for patients who are not candidates for surgery or who prefer less invasive options.

Canada

Headquartered in Ontario, Canada, SpinaFX is working to introduce minimally invasive, image-guided solutions to the market that benefit patients, physicians, facilities and payers. SpinaFX Medical's flagship treatment solution involves the intravertebral injection of a mixture of oxygen and ozone gas into a contained herniated disc for relief of back and leg pain. This technology is not currently approved for sale by regulatory agencies in the U.S., Canada, EU or elsewhere.

8750 Jane St, Unit 16, Vaughan, Ontario L4K 2M9, CA

SpinaFX

Company Details